Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
However, with the impending loss of exclusivity, J&J is focusing on newer therapies like Tremfya (guselkumab) to sustain growth in its immunology portfolio
doi: 10.3390/ijms25137076, 37
- S dng sn phm 2 ln/ngy (sng v ti) sn phm pht huy cng dng mt cch tt nht
On the heels of Regenerons combinations, Scholar Rocks released results from EMBRAZE, a 24-week Phase 2 study of tirzepatide with or without their anti-(latent) myostatin antibody, apetigromab
US$ 22.37
US$ 20.97
US$ 22.21
US$ 24.72
US$ 25.35
US$ 21.70
US$ 24.44
US$ 25.35
